Valerie Delpech

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7158582/publications.pdf

Version: 2024-02-01

71102 74163 7,255 196 41 75 citations h-index g-index papers 199 199 199 8803 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	COVIDâ€19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVIDâ€19 pandemic in England. HIV Medicine, 2022, 23, 90-102.	2.2	12
2	Diagnosis delays in the UK according to pre or postmigration acquisition of HIV. Aids, 2022, 36, 415-422.	2.2	3
3	UK guideline for the use of HIV postâ€exposure prophylaxisÂ2021. HIV Medicine, 2022, 23, 494-545.	2.2	10
4	Covidâ€19 First Wave Impact National Survey for HIV Clinicians by Public Health England (PHE), the British HIV Association (BHIVA) and the Children's HIV Association (CHIVA). HIV Medicine, 2022, , .	2.2	0
5	Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40Âyears on. HIV Medicine, 2022, 23, 978-989.	2.2	5
6	Factors associated with offering HIV testing to people aged ≥ 50 years: A qualitative study. International Journal of STD and AIDS, 2022, 33, 289-295.	1.1	3
7	Does being on HIV antiretroviral therapy increase the risk of syphilis? An analysis of a large national cohort of MSM living with HIV in England 2009–2016. Sexually Transmitted Infections, 2021, 97, 221-225.	1.9	3
8	HIV prevalence and HIV clinical outcomes of transgender and genderâ€diverse people in England. HIV Medicine, 2021, 22, 131-139.	2.2	4
9	Trends and predictors of linkage to HIV outpatient care following diagnosis in the era of expanded testing in England, Wales and Northern Ireland: Results of a national cohort study. HIV Medicine, 2021, 22, 491-501.	2.2	2
10	The association between use of chemsex drugs and HIV clinic attendance among gay and bisexual men living with HIV in London. HIV Medicine, 2021, 22, 641-649.	2.2	7
11	Minimum dataset for monitoring national human immunodeficiency virus pre-exposure prophylaxis (HIV PrEP) programmes: a five-nation consensus, 2019. Eurosurveillance, 2021, 26, .	7.0	3
12	Trends in HIV incidence between 2013–2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort study. PLoS Medicine, 2021, 18, e1003677.	8.4	13
13	The success of HIV combination prevention: The Dean Street model. HIV Medicine, 2021, 22, 892-897.	2.2	8
14	Quality of life among people living with HIV in England and the Netherlands: a population-based study. Lancet Regional Health - Europe, The, 2021, 8, 100177.	5.6	13
15	How older people living with HIV narrate their quality of life: Tensions with quantitative approaches to quality-of-life research. SSM Qualitative Research in Health, 2021, 1, 100018.	1.5	1
16	Brief report: HIV-related healthcare stigma/discrimination and unmet needs among persons living with HIV in England and Wales. Preventive Medicine Reports, 2021, 24, 101580.	1.8	4
17	Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study. Lancet HIV,the, 2021, 8, e747-e754.	4.7	1
18	Linkage of Whole Genome Sequencing, Epidemiological, and Clinical Data to Understand the Genetic Diversity and Clinical Outcomes of Shigella flexneri among Men Who Have Sex with Men in England. Microbiology Spectrum, 2021, 9, e0121321.	3.0	3

#	Article	IF	CITATIONS
19	HIV testing strategies outside of health care settings in the European Union (EU)/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance. HIV Medicine, 2020, 21, 142-162.	2.2	22
20	HIV testing strategies employed in health care settings in the European Union/European Economic Area (EU/EEA): evidence from a systematic review. HIV Medicine, 2020, 21, 163-179.	2.2	20
21	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	5.8	16
22	Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. Journal of Antimicrobial Chemotherapy, 2020, 75, 3311-3318.	3.0	15
23	Sexual risk and HIV testing disconnect in men who have sex with men (MSM) recruited to an online HIV selfâ€testing trial. HIV Medicine, 2020, 21, 588-598.	2.2	7
24	The impact of HIV infection on tuberculosis transmission in a country with low tuberculosis incidence: a national retrospective study using molecular epidemiology. BMC Medicine, 2020, 18, 385.	5.5	10
25	Evaluating the impact of post-trial implementation of RHIVA nurse-led HIV screening on HIV testing, diagnosis and earlier diagnosis in general practice in London, UK. EClinicalMedicine, 2020, 19, 100229.	7.1	9
26	Monitoring of older HIVâ€1â€positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. HIV Medicine, 2020, 21, 409-417.	2.2	4
27	A call to action toward integrated testing and earlier care for viral hepatitis, HIV, STIs and TB. HIV Medicine, 2020, 21, 403-408.	2.2	0
28	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIVâ€₁ resistance mutation. HIV Medicine, 2020, 21, 309-321.	2.2	3
29	British HIV Association/British Association for Sexual Health and HIV/British Infection Association adult HIV testing guidelines 2020. HIV Medicine, 2020, 21, 1-26.	2.2	14
30	HIV-1 Transmission Patterns in Men Who Have Sex with Men: Insights from Genetic Source Attribution Analysis. AIDS Research and Human Retroviruses, 2019, 35, 805-813.	1.1	8
31	Cause of death among HIV patients in London in 2016. HIV Medicine, 2019, 20, 628-633.	2.2	11
32	<scp>HIV</scp> coinfection among persons diagnosed with hepatitis B in England in 2008–2014. HIV Medicine, 2019, 20, 255-263.	2.2	7
33	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 746-753.	3.0	7
34	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. Aids, 2019, 33, 133-143.	2.2	20
35	<scp>HIV</scp> care cost in England: a crossâ€sectional analysis of antiretroviral treatment and the impact of generic introduction. HIV Medicine, 2019, 20, 377-391.	2.2	9
36	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV. Journal of Virus Eradication, 2019, 5, 20	4-21.1.	6

#	Article	IF	CITATIONS
37	Estimating the â€^PrEP Gap': how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance, 2019, 24, .	7.0	57
38	Current experiences of accessing and using HIV pre-exposure prophylaxis (PrEP) in the United Kingdom: a cross-sectional online survey, May to July 2019. Eurosurveillance, 2019, 24, .	7.0	13
39	Experience of primary care for people with HIV: a mixed-method analysis. BJGP Open, 2019, 3, bjgpopen19X101665.	1.8	8
40	Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control. Journal of Infectious Diseases, 2018, 217, 1522-1529.	4.0	32
41	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	5.8	105
42	The HIV epidemic: global and United Kingdom trends. Medicine, 2018, 46, 269-271.	0.4	2
43	Sexualized drug use (â€~chemsex') and highâ€risk sexual behaviours in <scp>HIV</scp> â€positive men who have sex with men. HIV Medicine, 2018, 19, 261-270.	2.2	163
44	Experiences of stigma and discrimination in social and healthcare settings among trans people living with HIV in the UK. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 836-843.	1.2	27
45	Factors associated with delayed linkage to care following <scp>HIV</scp> diagnosis in the <scp>WHO</scp> European Region. HIV Medicine, 2018, 19, 40-46.	2.2	9
46	What is the overlap between HIV and shigellosis epidemics in England: further evidence of MSM transmission?. Sexually Transmitted Infections, 2018, 94, 67-71.	1.9	27
47	<scp>HIV</scp> testing in persons diagnosed with hepatitis B and C. HIV Medicine, 2018, 19, e54-e55.	2.2	3
48	Comparison of cluster-based and source-attribution methods for estimating transmission risk using large HIV sequence databases. Epidemics, 2018, 23, 1-10.	3.0	37
49	Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation. Lancet Infectious Diseases, The, 2018, 18, 85-94.	9.1	80
50	Factors associated with testing for HIV in people aged ≥50Âyears: a qualitative study. BMC Public Health, 2018, 18, 1204.	2.9	23
51	Trends in human immunodeficiency virus diagnoses among men who have sex with men in North America, Western Europe, and Australia, 2000–2014. Annals of Epidemiology, 2018, 28, 874-880.	1.9	20
52	HIV incidence among sexual health clinic attendees in England: First estimates for black African heterosexuals using a biomarker, 2009-2013. PLoS ONE, 2018, 13, e0197939.	2.5	6
53	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. Clinical Infectious Diseases, 2018, 69, 1136-1143.	5.8	5
54	Ethical considerations in global HIV phylogenetic research. Lancet HIV, the, 2018, 5, e656-e666.	4.7	39

#	Article	IF	CITATIONS
55	Infectious disease testing of UK-bound refugees: a population-based, cross-sectional study. BMC Medicine, 2018, 16, 143.	5.5	21
56	The people living with HIV stigma survey UK 2015: HIV-related sexual rejection and other experiences of stigma and discrimination among gay and heterosexual men. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1189-1196.	1.2	15
57	Towards elimination of <scp>HIV</scp> transmission, <scp>AIDS</scp> and <scp>HIV</scp> â€related deaths in the <scp>UK</scp> . HIV Medicine, 2018, 19, 505-512.	2.2	45
58	Tuberculosis infection and disease in people living with HIV in countries with low tuberculosis incidence. International Journal of Tuberculosis and Lung Disease, 2018, 22, 713-722.	1.2	11
59	Prevalence of diagnosed HIV infection among persons with hepatitis C virus infection: England, 2008–2014. HIV Medicine, 2018, 19, 708-715.	2.2	9
60	The People Living with HIV STIGMASurvey UK 2015: Stigmatising experiences and dental care. British Dental Journal, 2018, 225, 143-150.	0.6	10
61	Trends in, and factors associated with, HIV infection amongst tuberculosis patients in the era of anti-retroviral therapy: a retrospective study in England, Wales and Northern Ireland. BMC Medicine, 2018, 16, 85.	5.5	5
62	Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. Journal of Infectious Diseases, 2018, 218, 1767-1772.	4.0	13
63	Scaleâ€up of <scp>HIV</scp> selfâ€testing. HIV Medicine, 2018, 19, e72.	2.2	7
64	Monitoring the HIV continuum of care in key populations across Europe and Central Asia. HIV Medicine, 2018, 19, 431-439.	2.2	19
65	Linkage to HIV care following diagnosis in the WHO European Region: A systematic review and meta-analysis, 2006-2017. PLoS ONE, 2018, 13, e0192403.	2.5	25
66	Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data. Lancet HIV,the, 2018, 5, e309-e316.	4.7	38
67	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. Lancet HIV,the, 2018, 5, e301-e308.	4.7	34
68	Where do we diagnose HIV infection? Monitoring new diagnoses made in nontraditional settings in England, Wales and Northern Ireland. HIV Medicine, 2018, 19, 465-474.	2.2	5
69	HIV and trans and non-binary people in the UK. Sexually Transmitted Infections, 2018, 94, 318-319.	1.9	20
70	Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral therapy compared with the general population: an analysis of a national observational cohort. Lancet Public Health, The, 2017, 2, e35-e46.	10.0	268
71	HIV incidence in an open national cohort of men who have sex with men attending sexually transmitted infection clinics in England. HIV Medicine, 2017, 18, 615-622.	2.2	17
72	<scp>HIV</scp> continuum of care in Europe and Central Asia. HIV Medicine, 2017, 18, 490-499.	2.2	29

#	Article	IF	Citations
73	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV,the, 2017, 4, e295-e302.	4.7	47
74	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. Clinical Infectious Diseases, 2017, 64, 1644-1656.	5.8	46
75	New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004–15: an analysis of surveillance data. Lancet HIV,the, 2017, 4, e514-e521.	4.7	87
76	Injecting drug use predicts active tuberculosis in a national cohort of people living with HIV. Aids, 2017, 31, 2403-2413.	2.2	6
77	The continuum of HIV care in South Africa. Aids, 2017, 31, 545-552.	2.2	43
78	Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK. Journal of Antimicrobial Chemotherapy, 2017, 72, 227-234.	3.0	23
79	Recent trends and patterns in <scp>HIV</scp> †transmitted drug resistance in the United Kingdom. HIV Medicine, 2017, 18, 204-213.	2.2	61
80	Development and application of a new measure of engagement in outâ€patient <scp>HIV</scp> care. HIV Medicine, 2017, 18, 267-274.	2.2	17
81	Monitoring of the HIV Epidemic Using Routinely Collected Data: The Case of the United Kingdom. AIDS and Behavior, 2017, 21, 83-90.	2.7	21
82	Effectiveness and cost-effectiveness of implementing HIV testing in primary care in East London: protocol for an interrupted time series analysis. BMJ Open, 2017, 7, e018163.	1.9	2
83	Barriers and facilitators to HIV testing in people age 50 and above: a systematic review. Clinical Medicine, 2017, 17, 508-520.	1.9	20
84	REACH: a mixed-methods study to investigate the measurement, prediction and improvement of retention and engagement in outpatient HIV care. Health Services and Delivery Research, 2017, 5, 1-160.	1.4	12
85	The menopause transition in women living with HIV: current evidence and future avenues of research. Journal of Virus Eradication, 2016, 2, 114-116.	0.5	17
86	Loss to Follow-Up After Pregnancy Among Sub-Saharan Africa-Born Women Living With Human Immunodeficiency Virus in England, Wales and Northern Ireland. Sexually Transmitted Diseases, 2016, 43, 283-289.	1.7	8
87	A Successful Strategy to Reduce Loss to Follow-Up in HIV Outpatient Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e19-e20.	2.1	0
88	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clinical Infectious Diseases, 2016, 62, 1072-1080.	5.8	122
89	Estimated cost per <scp>HIV</scp> infection diagnosed through routine <scp>HIV</scp> testing offered in acute general medical admission units and general practice settings in England. HIV Medicine, 2016, 17, 247-254.	2.2	3
90	Age and life course location as interpretive resources for decisions regarding disclosure of HIV to parents and children: Findings from the HIV and later life study. Journal of Aging Studies, 2016, 38, 81-91.	1.4	15

#	Article	IF	Citations
91	The impact of the menopause transition on the health and wellbeing of women living with HIV: A narrative review. Maturitas, 2016, 88, 76-83.	2.4	36
92	HIV pre-test information, discussion or counselling? A review of guidance relevant to the WHO European Region. International Journal of STD and AIDS, 2016, 27, 97-104.	1.1	10
93	Virological failure and development of new resistance mutations according to <scp>CD</scp> 4 count at combination antiretroviral therapy initiation. HIV Medicine, 2016, 17, 368-372.	2.2	7
94	Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study. Lancet HIV,the, 2016, 3, e94-e104.	4.7	68
95	Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. Journal of Infectious Diseases, 2016, 213, 1410-1418.	4.0	67
96	The menopause transition in women living with HIV: current evidence and future avenues of research. Journal of Virus Eradication, 2016, 2, 114-6.	0.5	9
97	A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology, 2015, 27, 1.	2.7	6
98	Restricted access to antiretroviral treatment for undocumented migrants: a bottle neck to control the HIV epidemic in the EU/EEA. BMC Public Health, 2015, 15, 1228.	2.9	49
99	Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study. BMC Medicine, 2015, 13, 297.	5.5	40
100	Delivery of <scp>HIV</scp> test results, postâ€test discussion and referral in health care settings: a review of guidance for <scp>E</scp> uropean countries. HIV Medicine, 2015, 16, 620-627.	2.2	6
101	Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. Aids, 2015, 29, 1855-1862.	2.2	49
102	CD4+ cell count responses to antiretroviral therapy are not impaired in HIV-infected individuals with tuberculosis co-infection. Aids, 2015, 29, 1363-1368.	2.2	5
103	A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. Aids, 2015, 29, 1917-1925.	2.2	41
104	Projected Lifetime Healthcare Costs Associated with HIV Infection. PLoS ONE, 2015, 10, e0125018.	2.5	47
105	Impact of TB on the survival of people living with HIV infection in England, Wales and Northern Ireland. Thorax, 2015, 70, 566-573.	5.6	31
106	Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV,the, 2015, 2, e243-e251.	4.7	35
107	Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial. Lancet HIV,the, 2015, 2, e229-e235.	4.7	37
108	GBD 2013 and HIV incidence in high income countries. Lancet, The, 2015, 385, 1177.	13.7	6

#	Article	IF	CITATIONS
109	Modelling the HIV epidemic among MSM in the United Kingdom. Aids, 2015, 29, 339-349.	2.2	39
110	A systematic review of post-migration acquisition of HIV among migrants from countries with generalised HIV epidemics living in Europe: mplications for effectively managing HIV prevention programmes and policy. BMC Public Health, 2015, 15, 561.	2.9	110
111	An overview of the HIV epidemic among men who have sex with men in the United Kingdom, 1999–2013. Eurosurveillance, 2015, 20, .	7.0	17
112	Migrant health and infectious diseases in the UK: findings from the last 10 years of surveillance. Journal of Public Health, 2014, 36, 28-35.	1.8	21
113	Trends in HIV Diagnoses, HIV Care, and Uptake of Antiretroviral Therapy Among Heterosexual Adults in England, Wales, and Northern Ireland. Sexually Transmitted Diseases, 2014, 41, 257-265.	1.7	17
114	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. Aids, 2014, 28, 1193-1202.	2.2	453
115	Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions. Aids, 2014, 28, 1967-1975.	2.2	69
116	WHO â€Treatment as Prevention' guidelines are unlikely to decrease HIV transmission in the UK unless undiagnosed HIV infections are reduced. Aids, 2014, 28, 281-283.	2.2	24
117	Recent infection testing algorithm (RITA) applied to new HIV diagnoses in England, Wales and Northern Ireland, 2009 to 2011. Eurosurveillance, 2014, 19, .	7.0	36
118	Death from AIDS is preventable, so why are people still dying of AIDS in Europe?. Eurosurveillance, 2014, 19, 20973.	7.0	2
119	The HIV epidemic: global and UK trends. Medicine, 2013, 41, 417-419.	0.4	7
120	Quality of <scp>HIV</scp> care in the <scp>U</scp> nited <scp>K</scp> ingdom: key indicators for the first 12 months from <scp>HIV</scp> diagnosis. HIV Medicine, 2013, 14, 19-24.	2.2	27
121	Conclusions from the <scp>HIV</scp> in <scp>E</scp> urope <scp>C</scp> openhagen 2012 <scp>C</scp> onference and ways forward: working together for optimal <scp>HIV</scp> testing and earlier care. HIV Medicine, 2013, 14, 1-5.	2.2	6
122	HIV in the UK: test, test, and test again. Lancet, The, 2013, 382, 1687-1688.	13.7	11
123	HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study. Lancet Infectious Diseases, The, 2013, 13, 313-318.	9.1	100
124	<scp>HIV</scp> treatment as prevention among men who have sex with men in the <scp>UK</scp> : is transmission controlled by universal access to <scp>HIV</scp> treatment and care?. HIV Medicine, 2013, 14, 563-570.	2.2	37
125	Automated analysis of phylogenetic clusters. BMC Bioinformatics, 2013, 14, 317.	2.6	305
126	Increasing <i>Pneumocystis</i> Pneumonia, England, UK, 2000–2010. Emerging Infectious Diseases, 2013, 19, 386-92.	4.3	140

#	Article	IF	Citations
127	Persistence of HIV-1 Transmitted Drug Resistance Mutations. Journal of Infectious Diseases, 2013, 208, 1459-1463.	4.0	92
128	Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age and Ageing, 2013, 42, 520-526.	1.6	23
129	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	5.8	88
130	Position statement on the use of antiretroviral therapy to reduce <scp>HIV</scp> transmission, <scp>J</scp> anuary 2013: The <scp>B</scp> ritish <scp>HIV A</scp> ssociation (<scp>BHIVA</scp>) and the <scp>E</scp> xpert <scp>A</scp> dvisory <scp>G</scp> roup on <scp>AIDS</scp> (<scp>EAGA</scp>). HIV Medicine, 2013, 14, 259-262.	2.2	17
131	Tenâ€year mortality trends among persons diagnosed with <scp>HIV</scp> infection in <scp>E</scp> ngland and <scp>W</scp> ales in the era of antiretroviral therapy: <scp>AIDS</scp> remains a silent killer. HIV Medicine, 2013, 14, 596-604.	2.2	53
132	The case for indicator conditionâ€guided <scp>HIV</scp> screening. HIV Medicine, 2013, 14, 445-448.	2.2	29
133	HIV testing in black Africans living in England. Epidemiology and Infection, 2013, 141, 1741-1748.	2.1	6
134	Decreasing incidence of tuberculosis among heterosexuals living with diagnosed HIV in England and Wales. Aids, 2013, 27, 1151-1157.	2.2	18
135	Increased HIV Incidence in Men Who Have Sex with Men Despite High Levels of ART-Induced Viral Suppression: Analysis of an Extensively Documented Epidemic. PLoS ONE, 2013, 8, e55312.	2.5	197
136	Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ, The, 2012, 345, e5253-e5253.	6.0	44
137	Projected life expectancy of people with HIV according to timing of diagnosis. Aids, 2012, 26, 335-343.	2.2	350
138	O14â€Investigating the recent infection testing algorithm (RITA): predictors of recent HIV infection among GUM clinic attendees: Abstract O14 Table 1. Sexually Transmitted Infections, 2012, 88, A5.3-A6.	1.9	1
139	Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. Aids, 2012, 26, 87-94.	2.2	65
140	A new method to assign country of HIV infection among heterosexuals born abroad and diagnosed with HIV. Aids, 2012, 26, 1961-1966.	2.2	88
141	Tuberculosis and HIV co-infection in healthcare workers in England and Wales, 1999–2005. Epidemiology and Infection, 2012, 140, 1873-1879.	2.1	1
142	Late HIV diagnosis in Europe: A call for increased testing and awareness among general practitioners. European Journal of General Practice, 2012, 18, 181-186.	2.0	27
143	Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells∫î¼L in the UK. HIV Medicine, 2012, 13, 73-78.	2.2	4
144	Evaluating the extent of potential resistance to preâ€exposure prophylaxis within the <scp>UK HIV</scp> â€1â€infectious population of men who have sex with men. HIV Medicine, 2012, 13, 309-314.	2.2	11

#	Article	IF	CITATIONS
145	Safe travels? <scp>HIV</scp> transmission among Britons travelling abroad. HIV Medicine, 2012, 13, 315-317.	2.2	29
146	The Recent Infection Testing Algorithm (RITA) in clinical practice: a survey of HIV clinicians in England and Northern Ireland. HIV Medicine, 2012, 13, 444-447.	2.2	7
147	<scp>HIV</scp> testing in community settings in resourceâ€rich countries: a systematic review of the evidence. HIV Medicine, 2012, 13, 416-426.	2.2	101
148	Editorial - HIV Surveillance: The Conscience of the Epidemic. Open AIDS Journal, 2012, 6, 65-66.	0.5	7
149	Auditing National HIV Guidelines and Policies: The United Kingdom CD4 Surveillance Scheme. Open AIDS Journal, 2012, 6, 149-155.	0.5	21
150	The burden of TBâ€"HIV in the EU: how much do we know? A survey of surveillance practices and results. European Respiratory Journal, 2011, 38, 1374-1381.	6.7	23
151	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ: British Medical Journal, 2011, 343, d6016-d6016.	2.3	282
152	Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study. Antiviral Therapy, 2011, 16, 805-814.	1.0	36
153	Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters. HIV Medicine, 2011, 12, 289-298.	2.2	20
154	Travel for HIV care in England: a choice or a necessity?. HIV Medicine, 2011, 12, 361-366.	2.2	13
155	Authors' response to Drs Scourfield, Jackson and Nelson. HIV Medicine, 2011, 12, 450-451.	2.2	0
156	Tuberculosis and HIV co-infection in European Union and European Economic Area countries. European Respiratory Journal, 2011, 38, 1382-1392.	6.7	37
157	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2011, 66, 1886-1896.	3.0	56
158	Circumcision Among Men Who Have Sex With Men in London, United Kingdom: An Unlikely Strategy for HIV Prevention. Sexually Transmitted Diseases, 2011, 38, 928-931.	1.7	10
159	Changing Patterns of Sexual Risk Behavior Among London Gay Men: 1998–2008. Sexually Transmitted Diseases, 2011, 38, 221-229.	1.7	49
160	Men who have sex with men: estimating the size of at-risk populations in London primary care trusts. International Journal of STD and AIDS, 2011, 22, 25-29.	1.1	9
161	Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. Aids, 2010, 24, 2849-2858.	2.2	36
162	HIV transmission and high rates of late diagnoses among adults aged 50 years and over. Aids, 2010, 24, 2109-2115.	2.2	192

#	Article	IF	Citations
163	HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antiviral Therapy, 2010, 15, 985-991.	1.0	17
164	Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations (sup) * (sup). HIV Medicine, 2010, 11, 432-438.	2.2	28
165	Risk factors for recurrent tuberculosis in England and Wales, 1998-2005. Thorax, 2010, 65, 310-314.	5.6	40
166	Monitoring HIV testing in diverse healthcare settings: results from a sentinel surveillance pilot study. Sexually Transmitted Infections, 2010, 86, 360-365.	1.9	11
167	Data linkage reduces loss to follow-up in an observational HIV cohort study. Journal of Clinical Epidemiology, 2010, 63, 1101-1109.	5.0	25
168	Late diagnosis in the HAART era: proposed common definitions and associations with mortality. Aids, 2010, 24, 723-727.	2.2	72
169	Epidemiology and clinical presentation of gonorrhoea in England and Wales: findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme 2001-2006. Sexually Transmitted Infections, 2009, 85, 317-321.	1.9	22
170	Trends in HIV testing and recording of HIV status in the UK primary care setting: a retrospective cohort study 1995-2005. Sexually Transmitted Infections, 2009, 85, 520-526.	1.9	21
171	Tuberculosis among people with HIV infection in the United Kingdom: opportunities for prevention?. Aids, 2009, 23, 2507-2515.	2.2	38
172	Primary care consultations and costs among HIV-positive individuals in UK primary care 1995-2005: a cohort study. Sexually Transmitted Infections, 2009, 85, 543-549.	1.9	7
173	Testing for HIV: concise guidance. Clinical Medicine, 2009, 9, 471-476.	1.9	33
174	The global epidemiology of HIV. Medicine, 2009, 37, 317-320.	0.4	9
175	The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Medicine, 2009, 10, 35-43.	2.2	24
176	Reemergence of the HIV Epidemic Among Men Who Have Sex With Men in North America, Western Europe, and Australia, 1996–2005. Annals of Epidemiology, 2009, 19, 423-431.	1.9	304
177	AIDS case reporting: do we still need it?. Lancet, The, 2009, 373, 181-183.	13.7	7
178	HIV testing in the UK. Lancet, The, 2009, 374, 376-377.	13.7	4
179	Molecular epidemiology of tuberculosis in England, 1998. International Journal of Tuberculosis and Lung Disease, 2009, 13, 201-7.	1.2	19
180	Could male circumcision reduce HIV incidence in the UK?. HIV Medicine, 2008, 9, 329-331.	2.2	5

#	Article	IF	CITATIONS
181	Investigating tuberculosis trends in England. Public Health, 2008, 122, 1302-1310.	2.9	27
182	Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 202-205.	2.1	15
183	The association between HIV and antituberculosis drug resistance. European Respiratory Journal, 2008, 32, 718-725.	6.7	14
184	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Aids, 2008, 22, 1943-1950.	2.2	16
185	The growing impact of HIV infection on the epidemiology of tuberculosis in England and Wales: 1999 2003. Thorax, 2007, 62, 672-676.	5.6	43
186	Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. Aids, 2007, 21, 1717-1721.	2.2	75
187	Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Aids, 2007, 21, 1423-1430.	2.2	30
188	CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997?2003. HIV Medicine, 2007, 8, 135-141.	2.2	36
189	Lessons learned from SARS: The experience of the Health Protection Agency, England. Public Health, 2006, 120, 27-32.	2.9	16
190	Monitoring the effectiveness of HIV and STI prevention initiatives in England, Wales, and Northern Ireland: where are we now?. Sexually Transmitted Infections, 2006, 82, 4-10.	1.9	18
191	The changing epidemiology of prevalent diagnosed HIV infections in England, Wales, and Northern Ireland, 1997 to 2003. Sexually Transmitted Infections, 2005, 81, 223-229.	1.9	17
192	SARS: UK public health response-past, present and future. Communicable Disease and Public Health / Phls, 2003, 6, 209-15.	0.4	1
193	Shigellosis Linked to Sex Venues, Australia. Emerging Infectious Diseases, 2002, 8, 862-864.	4.3	52
194	Ragweed in Australia. Aerobiologia, 2000, 16, 107-111.	1.7	29
195	Late summer and fall (March–May) pollen allergy and respiratory disease in Northern New South Wales, Australia. Annals of Allergy, Asthma and Immunology, 2000, 85, 374-381.	1.0	47
196	Factors influencing the presentation and care of elderly people in the Emergency Department. Medical Journal of Australia, 1992, 156, 197-200.	1.7	26